MAP3K8 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, expression levels of MOS in dasatinib non‐responder patients with CML were higher than those in dasatinib responders, and the expression of TPL2 tended to increase in dasatinib non‐responder patients compared with that in responder patients.